Kymera Therapeutics to Present at Upcoming September Investor Conferences

Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company, announced participation in two upcoming investor conferences. The first is the Morgan Stanley 19th Annual Global Healthcare Conference, featuring a live webcast on September 9, 2021, at 1:15 p.m. ET. The second is the H.C. Wainwright 23rd Annual Global Investment Conference, with an on-demand presentation available from September 13, 2021, at 7:00 a.m. ET. Webcasts can be accessed on the Company's website, where archived versions will be available for 30 days.

WATERTOWN, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at two upcoming investor conferences:

• Morgan Stanley 19th Annual Global Healthcare Conference: a fireside chat webcast will be available live on Thursday, September 9, 2021 at 1:15 p.m. ET.
• H.C. Wainwright 23rd Annual Global Investment Conference: an on demand webcast presentation will be available beginning on Monday, September 13, 2021 at 7:00 a.m. ET.

Presentation webcasts will be available under "Events and Presentations" in the Investors section of the Company's website at www.kymeratx.com. Archived webcast replays will be available on the website for approximately 30 days.

About Kymera Therapeutics
Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biopharmaceutical company founded with the mission to discover, develop, and commercialize transformative therapies while leading the evolution of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ platform enables the discovery of novel small molecule degraders designed to harness the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera’s initial programs are IRAK4, IRAKIMiD, and STAT3, each of which addresses high impact targets within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. Kymera’s goal is to be a fully integrated biopharmaceutical company at the forefront of this new class of protein degrader medicines, with a pipeline of novel degrader medicines targeting disease-causing proteins that were previously intractable.

Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a “Fierce 15” biotechnology company by FierceBiotech and has been recognized by the Boston Business Journal as one of Boston’s “Best Places to Work.” For more information about our people, science, and pipeline, please visit www.kymeratx.com or follow us on Twitter or LinkedIn.

Investor Contact:
Paul Cox
VP, Investor Relations and Communications
pcox@kymeratx.com
917-754-0207

Media Contact:
Lissette L. Steele
Verge Scientific Communications for Kymera Therapeutics
lsteele@vergescientific.com
202-930-4762

FAQ

What is Kymera Therapeutics presenting at the Morgan Stanley conference?

Kymera Therapeutics will present a fireside chat webcast on September 9, 2021, at 1:15 p.m. ET.

When will Kymera's presentation be available at the H.C. Wainwright conference?

An on-demand presentation by Kymera will be available starting September 13, 2021, at 7:00 a.m. ET.

Where can I watch the webcasts of Kymera Therapeutics' presentations?

The webcasts will be available under the 'Events and Presentations' section on Kymera's website.

How long will the archived webcasts be accessible?

Archived webcasts will be available for approximately 30 days after the events.

What is the focus of Kymera Therapeutics' research?

Kymera focuses on targeted protein degradation to develop novel small molecule protein degrader medicines for immune-inflammatory diseases and cancers.